Your notification will be processed by the MEB; the MEB or the IGJ may contact you. This depends on the notification.
The MEB investigates the notification of the medicine and carries out an impact analysis to determine whether the medicine is classified as critical. The criteria drawn up by the European Medicines Agency are applied. The MEB looks at the use of the medicine and the availability of alternatives in the Netherlands. The size of the patient group that would be affected is also taken into account.
If the impact analysis shows that there is a threat of a shortage of a critical medicine, the options for a solution will be further investigated.
If the marketing authorisation holder has submitted a request for temporarily different packaging when reporting to the notification centre, the marketing authorisation holder will be notified of this by the MEB.
Another possible solution for a temporary shortage may be that the Health and Youth Care Inspectorate (IGJ) temporarily gives permission to manufacturers, wholesalers or pharmacists to obtain a comparable medicine from abroad. Other solutions can be found on the MEB website.